Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$5.51
$4.00
$6.92
$200.47M2.16189,500 shs64,100 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.50
+0.4%
$19.00
$10.06
$21.72
$366.99M0.8250,159 shs24,077 shs
Organigram Holdings Inc. stock logo
OGI
Organigram
$1.86
$2.09
$0.97
$2.91
$191.95M1.091.35 million shs751,343 shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$39.65
+2.5%
$43.24
$6.07
$50.78
$2.16B1.051.28 million shs827,779 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.00%0.00%0.00%0.00%0.00%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
-0.51%+3.85%-3.33%+6.41%+84.43%
Organigram Holdings Inc. stock logo
OGI
Organigram
-3.63%-0.53%-30.60%+13.41%-7.68%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-3.15%-2.00%-6.95%+28.20%+510.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.8074 of 5 stars
2.53.00.00.02.51.71.3
Organigram Holdings Inc. stock logo
OGI
Organigram
N/AN/AN/AN/AN/AN/AN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.7849 of 5 stars
1.52.00.00.02.05.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0023.08% Upside
Organigram Holdings Inc. stock logo
OGI
Organigram
3.00
BuyN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
3.00
Buy$32.29-18.57% Downside

Current Analyst Ratings

Latest OGI, KMPH, NATR, and VERA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Organigram Holdings Inc. stock logo
OGI
Organigram
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
4/5/2024
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$56.00
3/27/2024
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00 ➝ $56.00
3/21/2024
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$21.00 ➝ $34.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
1/26/2024
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Strong-Buy$29.00 ➝ $37.00
1/26/2024
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$16.00 ➝ $21.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$10.72M0.00N/A23.28$3.63 per share0.00
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.82$1.59 per share12.24$8.36 per share2.33
Organigram Holdings Inc. stock logo
OGI
Organigram
$120.01M1.60N/AN/A$2.48 per share0.75
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/A$1.94 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.32N/A3.39%12.25%7.75%5/7/2024 (Confirmed)
Organigram Holdings Inc. stock logo
OGI
Organigram
-$184.34M-$0.80N/AN/AN/A-173.48%-30.94%-27.70%4/30/2024 (Estimated)
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$95.99M-$2.29N/AN/AN/AN/A-73.33%-50.79%5/9/2024 (Estimated)

Latest OGI, KMPH, NATR, and VERA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/AN/A  
3/20/2024Q4 2023
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$0.53-$0.58-$0.05-$0.58N/AN/A
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
2/13/2024Q1 2024
Organigram Holdings Inc. stock logo
OGI
Organigram
-$0.10-$0.14-$0.04-$0.14$28.61 million$26.78 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A
Organigram Holdings Inc. stock logo
OGI
Organigram
N/AN/AN/AN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.14
10.10
10.10
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29
Organigram Holdings Inc. stock logo
OGI
Organigram
N/A
4.28
2.11
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.49
7.71
7.71

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
19.39%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%
Organigram Holdings Inc. stock logo
OGI
Organigram
34.63%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
99.21%

Insider Ownership

CompanyInsider Ownership
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
1.10%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
4.70%
Organigram Holdings Inc. stock logo
OGI
Organigram
0.09%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
21.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
2234.51 million34.13 millionOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.94 millionOptionable
Organigram Holdings Inc. stock logo
OGI
Organigram
984103.20 million103.11 millionOptionable
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
5154.45 million42.64 millionOptionable

OGI, KMPH, NATR, and VERA Headlines

SourceHeadline
Profiting from ‘legal’ insider trading isn’t always easyProfiting from ‘legal’ insider trading isn’t always easy
statnews.com - April 26 at 3:57 AM
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from AnalystsVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from Analysts
americanbankingnews.com - April 21 at 2:12 AM
Rusfertide Shows Promise in Polycythemia VeraRusfertide Shows Promise in Polycythemia Vera
renalandurologynews.com - April 17 at 10:25 PM
Vera Therapeutics (NASDAQ:VERA) Trading Down 3% on Insider SellingVera Therapeutics (NASDAQ:VERA) Trading Down 3% on Insider Selling
americanbankingnews.com - April 16 at 1:26 AM
Vera Therapeutics (NASDAQ:VERA)  Shares Down 3%  After Insider SellingVera Therapeutics (NASDAQ:VERA) Shares Down 3% After Insider Selling
marketbeat.com - April 15 at 10:35 AM
Vera Therapeutics executive sells over $228k in company stockVera Therapeutics executive sells over $228k in company stock
investing.com - April 14 at 9:09 AM
Vanguard Group Inc. Raises Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Vanguard Group Inc. Raises Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)
marketbeat.com - April 14 at 4:16 AM
What about the company Vertex didn’t buy?What about the company Vertex didn’t buy?
statnews.com - April 13 at 7:39 PM
Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of StockInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of Stock
insidertrades.com - April 13 at 7:09 AM
Could This Stock Be the Next Biotech Buyout?Could This Stock Be the Next Biotech Buyout?
fool.com - April 13 at 5:29 AM
Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...
finance.yahoo.com - April 12 at 10:56 PM
Joseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockJoseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock
marketbeat.com - April 12 at 6:34 PM
Vertex wagers $4.9bn on Alpine kidney disease therapyVertex wagers $4.9bn on Alpine kidney disease therapy
pharmaphorum.com - April 11 at 8:49 PM
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsBiotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
msn.com - April 11 at 8:49 PM
2 Biotech Stocks Driving the Nasdaq Today2 Biotech Stocks Driving the Nasdaq Today
schaeffersresearch.com - April 11 at 1:41 PM
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2%Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2%
marketbeat.com - April 10 at 3:24 PM
Alpine Immune jumps on report of takeover interestAlpine Immune jumps on report of takeover interest
msn.com - April 10 at 1:24 PM
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down  on Insider SellingVera Therapeutics (NASDAQ:VERA) Shares Gap Down on Insider Selling
marketbeat.com - April 8 at 10:24 AM
Vera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in StockVera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in Stock
insidertrades.com - April 8 at 4:24 AM
Posttransplant Skin Disease: Consider Skin Cancer, Infection RisksPosttransplant Skin Disease: Consider Skin Cancer, Infection Risks
medscape.com - April 7 at 8:24 PM
Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using OptionsCommit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options
nasdaq.com - April 7 at 3:24 PM
Sean Grant Sells 99,828 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockSean Grant Sells 99,828 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock
marketbeat.com - April 6 at 12:37 AM
Guggenheim Reiterates Buy Rating for Vera Therapeutics (NASDAQ:VERA)Guggenheim Reiterates Buy Rating for Vera Therapeutics (NASDAQ:VERA)
marketbeat.com - April 5 at 11:10 AM
Vera Therapeutics (NASDAQ:VERA)  Shares Down 5.9% Vera Therapeutics (NASDAQ:VERA) Shares Down 5.9%
marketbeat.com - April 3 at 4:28 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Zevra Therapeutics logo

Zevra Therapeutics

NASDAQ:KMPH
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.
Organigram logo

Organigram

NASDAQ:OGI
Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
Vera Therapeutics logo

Vera Therapeutics

NASDAQ:VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.